Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
31.01B
Market cap31.01B
Price-Earnings ratio
-50.19
Price-Earnings ratio-50.19
Dividend yield
—
Dividend yield—
Average volume
3.86M
Average volume3.86M
High today
$150.00
High today$150.00
Low today
$140.99
Low today$140.99
Open price
$143.77
Open price$143.77
Volume
6.22M
Volume6.22M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

With a market cap of 31.01B, Insmed Incorporated(INSM) trades at $142.81. The stock has a price-to-earnings ratio of -50.19.

During the trading session on 2026-11-22, Insmed Incorporated(INSM) shares reached a daily high of $150.00 and a low of $140.99. At a current price of $142.81, the stock is +1.3% higher than the low and still -4.8% under the high.

Trading volume for Insmed Incorporated(INSM) stock has reached 6.22M, versus its average volume of 3.86M.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

INSM News

Simply Wall St 1d
Insmed Is Drawing Acquisition Interest

Sanofi is reportedly exploring a potential acquisition of Insmed (NasdaqGS: INSM), according to market sources referenced on 20 November 2026. Discussions are...

Insmed Is Drawing Acquisition Interest
Benzinga 2d
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains

French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is reportedly exploring a potential acquisition of Insmed Inc. (NASDAQ:INSM). As per a Thursday Bloomberg re...

Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
Benzinga 2d
Insmed Stock Rises: What's Going On?

Insmed Inc. (NASDAQ:INSM) shares are rising. A report surfaced that Sanofi is exploring an offer for the rare-disease drug developer. Insmed stock is gaining p...

Insmed Stock Rises: What's Going On?

Analyst ratings

96%

of 25 ratings
Buy
96%
Hold
4%
Sell
0%

More INSM News

Seeking Alpha 3d
Insmed may be worth $170 to $210 a share in takeover, analyst

Insmed (INSM) may be worth $170-$210 a share in a takeover after a report that Sanofi (SNY) is weighing a purchase of the drugmaker, according to an RBC analyst...

Insmed may be worth $170 to $210 a share in takeover, analyst
TipRanks 3d
Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO Capital

After Bloomberg reported that Sanofi (SNY) is evaluating a potential acquisition of Insmed (INSM), BMO Capital analyst Conor MacKay argued that adding Insmed’s...

Benzinga 3d
With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition...

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed
TipRanks 3d
Insmed’s New Pediatric Rare-Disease Study Offers an Early Pipeline Signal

Insmed (INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s INSPIRE AT study, officially titled “INSPIRE AT: Longitudinal Study...

TipRanks 3d
Sanofi eyeing takeover of U.S. drugmaker Insmed, Bloomberg reports

Sanofi (SNY) is exploring a potential acquisition of U.S. drugmaker Insmed (INSM), which could rank among the largest biopharma deals in recent years, Bloomberg...

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.